Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma

Indian Journal of Pathology and Microbiology

Volumn 53, Issue 1, 2010, Pages 20-23

  Malhan, Priya ^a   Husain, Nuzhat ^a   Bhalla, Shalini ^a   Gupta, Rakesh K ^a   Husain, Mazhar ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Astrocytoma; GBM; Micro vessel density; Morphometry; P53; PCNA

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYCLINE; PROTEIN P53;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MORPHOMETRICS; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ASTROCYTOMA; BIOMETRY; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 77749286970     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.59177     Document Type: Article

References (22)

1. Albright AL, Guthkelch AN, Packer RJ, Price RA, Rourke LB. Prognostic factors in pediatric brain-stem gliomas. J Neurosurg 1986;65:751-5.
2. Müller W, Afra D, Schröder R. Supratentorial recurrences of gliomas Morphological studies in relation to time intervals with astrocytomas. Acta Neurochir (Wein) 1977;37:75-91.
3. Roselli R, Iacoangeli M, Carapella CM, Scerrati M. The progression in astrocytic tumours. J Neurosurg Sci 1990;34:199-204.
4. Nakamura M, Konishi N, Tsunoda S, Hiasa Y, Tsuzuki T, Inui T, et al. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 1997;80:240-9.
5. Sallinen PK, Haapasalo HK, Visakorpi T, Helén PT, Rantala IS, Isola JJ, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA and S-phase fraction using archival paraffin - embedded samples. J Pathol 1994;174:275-82.
6. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 1999;58:46-53.
7. Pereira CR, Penaranda JMS, Salvado M V, Sobrido MJ, Abraldes M, Barros F et al. Value of MIB-1 labeling index (LI) in gliomas and its correlation with other prognostic factors. J Neurosurg 2000;44:203-10.
8. Haapasalo H, Isola J, Sallinen P, Kalimo H, Helin H, Rantala I. Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol 1993;142:1347-51.
9. Haapasalo HK, Sallinen PK, Helén P T, Rantala IS, Helin HJ, Isola JJ. Comparison of three quantitation methods for PCNA immunostaining: applicability and relation to survival in 83 astrocytic neoplasms. J Pathol 1993;171:207-14.
10. Yue W Y, Yu SH, Zhao SG, Chen ZP. Molecular markers relating to malignant progression in Grade II astrocytoma. J Neurosurg 2009;110:709-14.
11. Kirkegaard LJ, Devose PB, Yao B, Cohen C. Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas: Prognostic significance. Am J Pathol 1998;109:69-74.
12. Yahanda AM, Bruner JM, Donehower LA, Morrison RS. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol 1995;15:4249-59.
13. Ono Y, Tamiya T, Ichikawa T, Matsumoto K, Furuta T, Ohmoto T, et al. Accumulation of wild type p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol 1997;94:21-7.
14. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008;455:1129-33.
15. Ranuncolo SM, Varela M, Morandi A, Lastiri J, Christiansen S, Bal de Kier Joffé E, et al. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. J Neurooncol 2004;68:113-21.
16. Broniscer A, Baker SJ, West AN, Fraser MM, Proko E, Kocak M, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 2007;25:682-9.
17. Badhe PB, Chauhan P P, Mehta NK. Brainstem gliomas - a clinicopathological study of 45 cases with p53 immunohistochemistry. Indian J Cancer 2004;41:170-4.
18. Würdinger T, Tannous BA. Glioma angiogenesis: Towards novel RNA therapeutics. Cell Adh Migr 2009;3.epub ahead of print.
19. Bian XW, Du LL, Shi JQ, Cheng YS, Liu FX. Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas. Anal Quant Cytol Histol 2000;22:267-74.
20. Korkolopoulou P, Patsouris E, Kavantzas N, Konstantinidou AE, Christodoulou P, Thomas-Tsagli E, et al. Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms. Neuropathol Appl Neurobiol 2002;28:57-68.
21. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock J P, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998;88:513-20.
22. Folkerth RD. Histologic measures of angiogenesis in primary brain tumors. Cancer Treat Res 2004;117:79-95.